Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Treatment Resistent Cancers

Treatment Resistent Cancers

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.

Multiple sclerosis (Houndmills, Basingstoke, England)·2020

Same author

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.

EBioMedicine·2020

Same author

[Ocrelizumab for treatment of multiple sclerosis].

Der Nervenarzt·2020

Same author

Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.

Neurology(R) neuroimmunology & neuroinflammation·2020

Same author

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

EBioMedicine·2020

Same author

COVID-19 and management of neuroimmunological disorders.

Nature reviews. Neurology·2020

Search research articles

Related Experiment Video

Updated: Apr 12, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.

Jagadeesh Bayry¹, Hans-Peter Hartung², Srini V Kaveri¹

¹Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris F-75006, France; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohematology, Mumbai 400012, India.

Trends in Pharmacological Sciences

|May 25, 2015

Summary

Intravenous immunoglobulin (IVIg) therapy shows promise for relapsing-remitting multiple sclerosis (MS). However, uncertainties in treatment effectiveness may stem from patient variability and specific treatment parameters.

Keywords:

IVIg autoimmunity biomarkers immunotherapy inflammation multiple sclerosis

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Apr 12, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

Neurology
Immunology

Background:

Relapsing-remitting multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
Intravenous immunoglobulin (IVIg) therapy has emerged as a potential treatment option for MS, with some clinical trials showing positive outcomes.

Purpose of the Study:

To investigate the uncertainties surrounding the efficacy of IVIg therapy in relapsing-remitting multiple sclerosis.
To identify potential factors contributing to the variable responses observed in patients undergoing IVIg treatment.

Main Methods:

Review of existing clinical trial data on IVIg for MS.
Analysis of patient cohorts, treatment dosages, and treatment durations.

Main Results:

Clinical trials for IVIg in MS have yielded promising results but also revealed significant uncertainties.
Factors such as small patient numbers, patient heterogeneity, IVIg dosage variations, and treatment timing may influence therapeutic outcomes.

Conclusions:

Further research with standardized protocols and larger patient cohorts is needed to clarify the role of IVIg in managing relapsing-remitting MS.
Optimizing IVIg treatment parameters may enhance its effectiveness in MS patients.